1. Home
  2. REFI vs RZLT Comparison

REFI vs RZLT Comparison

Compare REFI & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Chicago Atlantic Real Estate Finance Inc.

REFI

Chicago Atlantic Real Estate Finance Inc.

HOLD

Current Price

$12.28

Market Cap

255.6M

Sector

Real Estate

ML Signal

HOLD

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$2.35

Market Cap

187.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REFI
RZLT
Founded
2021
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
255.6M
187.3M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
REFI
RZLT
Price
$12.28
$2.35
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$20.00
$12.33
AVG Volume (30 Days)
150.4K
15.0M
Earning Date
11-04-2025
02-11-2026
Dividend Yield
16.17%
N/A
EPS Growth
N/A
N/A
EPS
1.69
N/A
Revenue
$54,287,847.00
N/A
Revenue This Year
$13.78
N/A
Revenue Next Year
$4.07
N/A
P/E Ratio
$7.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.85
$1.07
52 Week High
$16.27
$11.46

Technical Indicators

Market Signals
Indicator
REFI
RZLT
Relative Strength Index (RSI) 38.72 31.49
Support Level $12.76 $2.16
Resistance Level $13.20 $2.82
Average True Range (ATR) 0.28 0.35
MACD -0.06 0.02
Stochastic Oscillator 10.45 74.37

Price Performance

Historical Comparison
REFI
RZLT

About REFI Chicago Atlantic Real Estate Finance Inc.

Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

Share on Social Networks: